According to a new market report published by Persistence Market
Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to
Witness Highest Growth by 2022”, the global osteoporosis
drugs market is estimated to be valued at US$11,226.1 Mn by the
end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to
2022, to account for US$14,786.7 Mn by 2022.
The global osteoporosis drugs market is witnessing significant growth
due to rising geriatric population and changing lifestyles impinging
bone health. Prevalence of osteoporosis is high among people aged 60
years and above. Moreover, increasing the prevalence of osteoporosis
in postmenopausal women, growing awareness about osteoporotic care,
and increasing investment in drug discovery and development are also
driving the growth of the market. However, there are various side
effects and complications associated with osteoporosis drugs such as
heartburn, irritable bowel syndrome, nausea, and ulcers in the
stomach or esophagus. Furthermore, patent expiration of osteoporosis
drugs also inhibits the growth of the market.The osteoporosis drugs
market is anticipated to grow from an estimated US$11,226.1 Mn by the
end of 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0%
during the forecast period.
In North America, the prevalence of osteoporosis is high primarily
due to increasing geriatric population, growing obesity, and rising
prevalence of lifestyle associated diseases in the region. According
to the National Osteoporosis Foundation, in 2013, approximately 54
million people in the U.S. aged 50 years and above were affected by
osteoporosis and low bone mass. According to the U.S. Department of
Health and Human Services, in the U.S., approximately 250,000 hip
fractures are associated with osteoporosis.
Need more information about Report methodology ? @
In Europe, increasing aging population, changing lifestyles, and
increasing consumer awareness about osteoporosis care are driving the
growth of the osteoporosis drug market. According to the
International Osteoporosis Foundation, approximately 5.5 million men
and 22 million women suffered from osteoporosis in 2010. Moreover,
according to International Osteoporosis Foundation, approximately
27.5 million people in Europe suffered from osteoporosis in 2010 and
the number is expected to reach 33.9 Mn by 2030.
However, the growth of osteoporosis market in Asia Pacific is much
due to rising geriatric population and changing lifestyles in the
region. Osteoporotic patients have a higher risk of hip fractures,
owing to a major cause of morbidity and mortality. According to the
International Osteoporosis Foundation, by 2050, approximately 50% of
the world’s osteoporosis hip fractures would occur in women in
Asia. In addition, according to a study on Epidemiology in
Osteoporosis in Japan by the National Centre for Biotechnology
Information, in 2011, approximately 15 million people suffered from
osteoporosis in Japan.
Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Merck & Co.
Inc., Novartis AG, Amgen, Inc., Actavis plc, Teva Pharmaceuticals
Industries Ltd., and Pfizer, Inc. are some of the major players of
osteoporosis drugs market.
Buy Full Market Report @
No comments:
Post a Comment